OSE Immuno: Invest Securities raises its target

(CercleFinance.com) - Invest Securities maintains its Buy rating on OSE Immuno shares, with a price target raised from 13.
5 to 14.7 euros.

The broker raises its target after OSE Immuno and the GERCOR consortium reported positive Ph II results for the TEDOPaM program in advanced pancreatic cancer.

The 1st results of the study show an improved survival rate for patients treated with the Tedopi/chemotherapy combination vs. chemotherapy alone.

Although we consider it unlikely that OSE Immuno will pursue developments in pancreatic cancer on its own, these data should, in our view, reinforce the interest of a Pharma partner in a global licensing agreement in a number of key indications", stresses the analyst.


Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.